Navigation Links
Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:3/17/2010

ATLANTA, March 17 /PRNewswire/ -- OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

Margo Klomp, M.D., of the Academic Medical Center (AMC) in Amsterdam, presented the data from 405 unselected patients treated at the AMC. The definite and probable stent thrombosis (ST) rate was 1.2 percent and no ST was reported between three months and one year. Dual anti-platelet therapy (DAPT) was recommended for one month and 16 of the patients were contra-indicated for DAPT, receiving only two weeks of clopidogrel post angioplasty.  The composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR) was 13.3 percent. The clinically driven TLR rate by means of PCI was 9.1 percent and by means of coronary artery bypass graft surgery (CABG) was 1.7 percent. Ten patients died of cardiac causes and 11 patients suffered MI, of which six were peri-procedural and five spontaneous.

"The Genous Bio-engineered R stent shows good clinical outcomes in this unselected patient population with predominantly complex lesions," said Margo Klomp, M.D., presenter and co-investigator of the study. "Furthermore, using this stent avoids the need for long term DAPT."

The mean age of the study population was 63 +/- 11 years and 72 percent of patients were male. In addition, 18 percent of patients in the study cohort had diabetes mellitus.  For the lesions treated, 75 percent were type B2/C lesions, 20 percent chronic total occlusion (CTO) lesions and 24 percent bifurcated lesions. The average stent length was 24.6 +/- 11.7 mm.

During a separate session, Dr Klomp presented the data of a patient treated with the Genous Bio-engineered R stent that underwent 6 and 18 months angiographic follow up.

"In our real world experience with the Genous Bio-engineered R stent, we have seen a significant regression of neointimal hyperplasia when we do longer term angiographic follow up," said Prof. Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam and a co-investigator of the study. "In several patients from this cohort, we saw a remarkable regression in intimal hyperplasia tissue between 6 and 18 month follow up."

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005.  The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies.  There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China.  OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.    

SOURCE OrbusNeich

Back to top

RELATED LINKS
http://www.OrbusNeich.com

'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Key Caldolor(R) Orthopedic Data to Be Presented at American Academy of Orthopaedic Surgeons Annual Meeting
3. STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting
4. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
5. Data From Three Clinical Studies of bioTheranostics Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
6. Nplate(R) Data From MDS Studies Presented at ASH
7. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
8. New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting
9. Amgen Highlights Data to be Presented at ASH
10. John Madden to Honor the NFLs Best Offensive Linemen with Madden Most Valuable Protectors Award Presented by Prilosec OTC(R)
11. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):